Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
SOUTH PLAINFIELD, N.J. and ROCHESTER, N.Y., May 09, 2017 -- Today, the University of Rochester School of Medicine and Dentistry and Admera Health announced that enrollment had commenced in a randomized clinical study evaluating the use of pharmacogenomics to guide pain management decisions related to acute dental surgery. Specifically, the study is seeking to determine if a preoperative chair-side pharmacogenomic algorithm can significantly enhance the efficacy of surgical pain management and to characterize the association between gene-drug interactions and clinical outcomes.
Admera Health, a molecular diagnostic company, will extract and sequence DNA samples provided by the University of Rochester. Sequencing will utilize Admera’s PGxOne™ Plus test, a 50 gene Next Generation Sequencing panel that interrogates nearly 200 different variants and provides recommendations for over 220 drugs based on an individual’s unique genetic makeup.
“It is well understood in the medical community that most acute surgical pain methods have shown inconsistent effects on pain relief and rely excessively on opioid use, which has associated dependency issues,” as stated by Admera CEO and President Guanghui Hu. “With the implementation of our PGxOne™ Plus test, we are confident that this study will demonstrate improved patient outcomes, similar to the way pharmacogenomics has been clinically validated in other therapeutic areas such as cardiovascular health, oncology, and psychiatric care. That is why we are excited to be working with the University of Rochester for this study.”
According to the CDC, opioid-involved deaths continue to increase and have reached epidemic status. In March, a United States Senate committee opened a probe into the practices of the top manufacturers of opioid drugs.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 [email protected]
